(VIANEWS) – WEBSTEP (WSTEP.OL), CAIRN HOMES PLC (C5H.IR), UCB (UCB.BR) are the highest payout ratio stocks on this list.
We have gathered information about stocks with the highest payout ratio so far. The payout ratio in itself isn’t a promise of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. WEBSTEP (WSTEP.OL)
106.92% Payout Ratio
Webstep ASA, together with its subsidiaries, provides information technology (IT) consultancy services to public and private businesses in Norway and Sweden. The company offers digitalization, cloud migration and integration, Internet of Things, machine learning, IT security, robotics, and analytics. Its services include consulting, digitalization, .Net, Java, open source, full stack, front and back end, user experience, integration, mobility, cloud apps, machine learning, business intelligence, big data, data warehousing, virtual robotics, Devops, application service management, and data science services; and cloud computing, cloud services, integration, sensor technology, product and service development, Beacons, enterprise user experience, web analysis, design team, Amazon Web, Azure, prediction, AI, mobility predictive modelling, predictive modelling, hackathon, business analysis, and search engine optimization services. The company serves banking, finance and insurance, public administration, agriculture and food production, IT and telecommunication, commerce, and transportation industries. The company was founded in 2000 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, WEBSTEP has a trailing twelve months EPS of kr1.38.
PE Ratio
WEBSTEP has a trailing twelve months price to earnings ratio of 19.54. Meaning, the purchaser of the share is investing kr19.54 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.66%.
Volume
Today’s last reported volume for WEBSTEP is 4055 which is 82.69% below its average volume of 23426.
2. CAIRN HOMES PLC (C5H.IR)
63.49% Payout Ratio
Cairn Homes plc operates as a homebuilder in Ireland. The company develops and sells residential properties. It is also involved in the rental of properties. The company was incorporated in 2014 and is based in Dublin, Ireland
Earnings Per Share
As for profitability, CAIRN HOMES PLC has a trailing twelve months EPS of €0.017.
PE Ratio
CAIRN HOMES PLC has a trailing twelve months price to earnings ratio of 61.18. Meaning, the purchaser of the share is investing €61.18 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.59%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 28.5%, now sitting on 617.36M for the twelve trailing months.
Moving Average
CAIRN HOMES PLC’s worth is higher than its 50-day moving average of €0.95 and above its 200-day moving average of €0.98.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Apr 20, 2023, the estimated forward annual dividend rate is 0.06 and the estimated forward annual dividend yield is 5.98%.
3. UCB (UCB.BR)
60.47% Payout Ratio
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, China, Italy, the United Kingdom, Ireland, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Earnings Per Share
As for profitability, UCB has a trailing twelve months EPS of €3.77.
PE Ratio
UCB has a trailing twelve months price to earnings ratio of 21.03. Meaning, the purchaser of the share is investing €21.03 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.81%.
Volume
Today’s last reported volume for UCB is 105041 which is 55.78% below its average volume of 237573.
4. SAMSE (SAMS.PA)
54.72% Payout Ratio
Samse SA distributes building materials and tools in France. The company offers public works, roads, and sanitation products; construction materials and structural works; plaster, ceiling, and insulation; frame and roof; wood and panels; doors, windows, and joinery; floor and wall coverings; electricity, plumbing, sanitary, and heating; terrace and garden products, as well as tools, materials, hardware, and security. It serves customers through approximately 80 points of sales in Auvergne-Rhône-Alpes, Paca, and Gard. The company was founded in 1920 and is headquartered in Grenoble, France. Samse SA is a subsidiary of Dumont Investissement.
Earnings Per Share
As for profitability, SAMSE has a trailing twelve months EPS of €13.74.
PE Ratio
SAMSE has a trailing twelve months price to earnings ratio of 13.98. Meaning, the purchaser of the share is investing €13.98 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.7%.
5. CORBION (CRBN.AS)
53.33% Payout Ratio
Corbion N.V. provides lactic acid and lactic acid derivatives, emulsifiers, functional enzyme blends, minerals, vitamins, and algae ingredients worldwide. The company offers ingredient solutions made from renewable resources for the food, home and personal care, animal nutrition, pharmaceutical, medical device, and bioplastics markets. It markets its products through a network of sales offices and distributors. The company was formerly known as CSM N.V. and changed its name to Corbion N.V. in October 2013. Corbion N.V. was founded in 1919 and is headquartered in Amsterdam, the Netherlands.
Earnings Per Share
As for profitability, CORBION has a trailing twelve months EPS of €1.05.
PE Ratio
CORBION has a trailing twelve months price to earnings ratio of 29.52. Meaning, the purchaser of the share is investing €29.52 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.26%.
Volume
Today’s last reported volume for CORBION is 30646 which is 60.47% below its average volume of 77531.
Yearly Top and Bottom Value
CORBION’s stock is valued at €31.00 at 16:10 EST, way under its 52-week high of €37.76 and way above its 52-week low of €23.80.
